Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Activating mutations of EZH2, an epigenetic regulator, are present in 20% of follicular lymphoma patients. Tazemetostat monotherapy showed clinically meaningful, durable responses. Serious treatment-related adverse events were reported in four (4%) of 99 patients.

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Epithelioid sarcoma is a rare and aggressive soft-tissue sarcomo subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on EZH2. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma.

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. At 24 months, progression-free survival was 77% in patients with stage IIIA NSCLC. Neoadjuant nivolumab could be added to platinum-based chemotherapy.

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue. It reduces expression of furin and downstream TGF-β1 and T GF-β2. Recurrence-free survival was 11.5 months for patients.

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Survival outcomes for patients with recurrent or advanced cervical cancer are poor. GX-188E vaccination has been shown to induce human papillomavirus (HPV) T-cell responses and cervical lesion regression in patients with cervical precancer. Treatment with GX-188E therapeutic vaccine plus pembrolizumab was safe and treatment-related adverse events were manageable.

Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial

Long-term follow-up results for the Costa Rica Vaccine Trial. Women aged 18–25 years were enrolled in the trial between June 28, 2004, and Dec 21, 2005. At year 11, vaccine efficacy against incident HPV 16/18-associated CIN2+ was 100% (95% CI 89·2–100·0) Vaccine efficacy was also 100% against HPV 16-associated. CIN

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. It has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. Median progression-free survival according to an independent review committee was 22.4 months.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Analysis of six randomized phases 3 trials were done to investigate non-inferiority of 3 months versus 6 months of adjuvant chemotherapy. For patients treated with CAPOX, 5-year overall survival was 82% versus 81% for those treated with FOLfox. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies, and cost associated with shorter treatment duration.

Departments

Recent Posts